As India grapples with a vaccine shortage, the Drug Controller General of India has formally approved another vaccine candidate — Sputnik V — under emergency use authorisation. Since January, India’s vaccination strategy has hinged almost entirely on Covishield — the AstraZeneca vaccine — and to a very limited extent, Covaxin. Another significant move by the government is in allowing foreign-made vaccines approved by regulatory agencies in the U.S., the U.K., Europe, Japan or those that find mention in the World Health Organization’s list of approved emergency use vaccines which can avoid conducting a local clinical trial but opt for a parallel bridging trial post-approval. Last year, Pfizer had approached Indian regulators for permission but a sticking point was over this question of the conduct of local trials. It is important to note that bridging trials are critical. A vaccine that is approved in a different country may have untoward effects in another population. Past learnings
Emancipation is seldom a linear progression to the finish; the hurdles are many, some entrenched in the mind. The passing of amendments to the Medical Termination of Pregnancy (MTP) Act in India recently is a step forward in recognising the rights of women, but is no giant leap. It does push the envelope way past how far the now antediluvian MTP Act of 1971 went, primarily by allowing the termination of pregnancy beyond 24 weeks if there are foetal anomalies. However, it also sets the decision on the shoulders of a medical board formed by State governments for this specific purpose. The amended Act also allows the termination of pregnancy until 20 weeks based on the opinion of one qualified doctor, an improvement from the consensus between the two doctors clause that was previously required. As per the amendment, unmarried women can also terminate their pregnancy, and by replacing the word ‘husband’ with the word ‘partner’, it, for the first time, takes the dialogue outside the
